Olmesartan Dosing
For adults with hypertension, start olmesartan medoxomil at 20 mg once daily, titrate to 40 mg once daily after 2 weeks if blood pressure remains uncontrolled, and use a lower starting dose in volume-depleted patients or those on diuretics. 1
Adult Dosing Regimen
Standard Dosing
- Initial dose: 20 mg once daily (monotherapy in euvolemic patients)
- Titration: Increase to 40 mg once daily after 2 weeks if BP remains elevated
- Maximum dose: 40 mg once daily (doses above 40 mg provide no additional benefit)
- Frequency: Once daily dosing only—twice-daily dosing offers no advantage 1
Volume-Depleted Patients
For patients with possible intravascular volume depletion (diuretic use, renal impairment), initiate olmesartan under close medical supervision with consideration of a lower starting dose. 1 This is critical because these patients are at higher risk for symptomatic hypotension.
Pediatric Dosing (≥6 Years)
Weight-Based Dosing
20 to <35 kg (44-77 lb):
- Initial: 10 mg once daily
- Maximum: 20 mg once daily (after 2 weeks if needed)
≥35 kg:
- Initial: 20 mg once daily
- Maximum: 40 mg once daily (after 2 weeks if needed)
Do not use olmesartan in children <1 year of age. 1
Suspension Preparation for Children Unable to Swallow Tablets
For a 2 mg/mL suspension (200 mL total):
- Add 50 mL purified water to 20 olmesartan 20 mg tablets in amber PET bottle
- Allow 5 minutes standing, then shake 1 minute/stand 1 minute (repeat 5 times total)
- Add 100 mL Ora-Sweet® and 50 mL Ora-Plus®, shake well
- Refrigerate at 2-8°C (36-46°F), stable for 4 weeks
- Shake well before each use 1
Special Population Adjustments
Renal Impairment
- Mild-to-moderate impairment: No dose adjustment required, though pharmacokinetic data show 39-82% higher drug exposure 2
- Severe renal impairment: Consider lower starting dose; maximum 20 mg daily (versus 40 mg in general population) 2
- Renal artery stenosis: Use with extreme caution—risk of acute renal failure with bilateral stenosis or stenosis in a solitary kidney 1
The increased plasma concentrations in renal impairment remain well below levels observed with 80 mg doses that were well-tolerated in clinical trials, supporting the safety of standard dosing in mild-to-moderate disease 2.
Hepatic Impairment
- Mild-to-moderate impairment (Child-Pugh ≤9): No dose adjustment required, though AUC increases 30-48% 2
- Severe hepatic impairment (Child-Pugh >9): Use with caution; specific dosing not established
Compensatory renal excretion increases with hepatic dysfunction, mitigating some accumulation risk 2.
Elderly Patients (≥65 Years)
- Standard dosing applies: No routine dose adjustment needed
- Pharmacokinetic considerations: Cmax and AUC up to 44% higher, half-life 12.8-16.5 hours (versus 10.6-12.3 hours in younger patients) 2
- Clinical efficacy: Olmesartan-based regimens achieve BP goals in 56-88% of elderly patients with stage 1-2 hypertension or isolated systolic hypertension 3
The higher drug exposure in elderly patients remains within safe ranges established in clinical trials 2.
Combination Therapy Strategy
When Monotherapy Fails
If BP remains uncontrolled after olmesartan 40 mg daily, add hydrochlorothiazide 12.5 mg daily, then titrate to 25 mg daily if needed. 4, 5 This stepwise approach achieves BP control in 87-93% of patients 5.
Alternative Combination
For patients requiring further intensification, add amlodipine 5 mg daily, titrating to 10 mg daily as needed 5. The triple combination (olmesartan/amlodipine/hydrochlorothiazide) is particularly effective in high-risk populations including those with diabetes, CKD, and chronic CVD 6.
Evidence for Combination vs. Uptitration
While dose-ranging studies suggest a flat dose-response curve for ARBs, dose-titration studies demonstrate significant BP improvements with olmesartan uptitration from 20 to 40 mg, translating to clinically meaningful increases in BP goal attainment 7. However, for patients inadequately controlled on olmesartan 20 mg, adding hydrochlorothiazide 12.5 mg is more effective than uptitrating to olmesartan 40 mg alone (71% vs. 62% response rate) 8.
Critical Contraindications and Warnings
Absolute Contraindications
- Do not co-administer with aliskiren in diabetic patients 1
- Pregnancy: Discontinue immediately when pregnancy detected—causes fetal renal dysfunction, oligohydramnios, and neonatal complications 1
Important Precautions
- Monitor electrolytes and renal function 2-4 weeks after initiation or dose changes 9
- Expected eGFR decline up to 30% is acceptable with RAAS inhibitors; persistent decline >30% warrants nephrology referral 9
- Avoid in bilateral renal artery stenosis due to acute renal failure risk 1, 10